On a mini hiring spree, CRO Altasciences nabs ex-Charles River exec

Canadian pharmaceuticals
Canadian CRO Altasciences also added a new chief scientific officer just last month. (Shutterstock)

Just a month ago, Altasciences grabbed CRO veteran Beatrice Setnik, Ph.D., as its new chief scientific officer; now, it’s at it again.

The Canadian biopharma services company said it has hired Lynne LeSauteur, Ph.D., as its vice president of immunochemistry and immunology.

LeSauteur comes out of the Human Health Therapeutics Research Center at the National Research Council of Canada where she helped discover, biomanufacture and characterize new biologics alongside life sciences companies.


De-risking the Development of Biotherapeutics Using Early Stage In Vitro Expression and Genetic Characterisation Tools

There is a high attrition rate during the development of biotherapeutics impacting the high cost of development. Early identification of the preferred expression host for manufacturing, along with lead candidate screening and material supply can help to reduce both attrition rates and cost.

RELATED: Syneos Health exec jumps ship to Canadian CRO Altasciences

Before this, she served a stint at fellow CRO Charles River Labs, where she established its immunology department.

Marie-Hélène Raigneau, EVP of research services at Altasciences, said: “We are extremely pleased to welcome Lynne to the team at Altasciences. The breadth of her experience in both preclinical and clinical drug development, including her in-depth knowledge of immunotoxicology, immunogenicity, immunoassays, molecular biology, and biomarkers, will continue to enhance scientific guidance to our growing base of small- to mid-size clients.”

Suggested Articles

Moderna’s shares shrunk by nearly 5% before the long holiday weekend Thursday after a report out by Stat said the biotech was delaying its trial.

The supermarket chain received an emergency authorization for its own home collection kit for COVID-19 testing, which includes a telehealth consult.

Helsinn Group and MEI Pharma penned a near $500 million biobucks pact for experimental blood cancer drug pracinostat back in 2016.